Caris Life Sciences (United States)
CAI
$20.00
+21.58%
Caris Life Sciences is a next-generation AI TechBio company that leverages comprehensive molecular profiling and artificial intelligence/machine learning algorithms to transform healthcare. As a patient-centric innovator in the biotechnology industry, it distinguishes itself by integrating AI-driven insights with molecular diagnostics to enable precision medicine. The current investor narrative centers on the company's rapid revenue growth trajectory, driven by its expanding pharma services and diagnostics business, alongside its recent transition to profitability in Q4 2025, which has sparked debate about the sustainability of its margin expansion and the scalability of its AI platform.…
CAI
Caris Life Sciences (United States)
$20.00
Investment Opinion: Should I buy CAI Today?
Rating: Buy. The thesis is that Caris's rapid revenue growth (78.8% YoY) and improving margins will drive a re-rating from current depressed levels, supported by a strong balance sheet and bullish analyst consensus.
Supporting Evidence: Revenue grew 78.8% YoY to $216.2M in Q1 2026, gross margin expanded to 65.4% from 47.2% a year ago, free cash flow turned positive at $22.5M, and the average analyst target of $27.00 implies 74% upside. The forward PS of 24.6x, while high, is a significant discount to the trailing PS of 55.55x, reflecting expected revenue growth. The PEG ratio of 0.48 suggests undervaluation relative to earnings growth, though forward EPS estimates of $1.04 are uncertain.
Risks & Conditions: The biggest risks are failure to sustain growth (revenue growth below 50%) and inability to achieve consistent profitability. This Buy rating would be downgraded to Hold if the stock approaches the analyst average target of $27 without new catalysts, or to Sell if revenue growth decelerates below 30% or the company reports a significant net loss. The stock appears undervalued relative to its growth potential but overvalued on absolute PS basis; the risk/reward is favorable given the 74% upside to the average target.
Sign up to view all
CAI 12-Month Price Forecast
Caris Life Sciences is a high-growth AI TechBio company with strong revenue momentum and improving profitability. The stock has been punished by the market, down 47% in a year, creating a potential value opportunity. The key to the bullish stance is the company's ability to sustain growth and achieve consistent profitability. If it does, the stock could re-rate significantly toward analyst targets. However, the high valuation and earnings volatility warrant medium confidence. An upgrade to high confidence would require multiple quarters of positive net income and sustained free cash flow.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Caris Life Sciences (United States)'s 12-month outlook, with a consensus price target around $27.00 and implied upside of +35.0% versus the current price.
Average Target
$27.00
0 analysts
Implied Upside
+35.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$21 - $36
Analyst target range
The stock is covered by 12 analysts, with a consensus recommendation of 'Buy' (mean score 1.54 on a 1-5 scale, where 1 is Strong Buy). The average price target is $27.00, implying 74% upside from the current price of $15.52. The target range spans from $21.00 (low) to $36.00 (high), indicating a wide dispersion of views. The high target of $36.00 assumes successful execution of the AI platform and sustained revenue growth, while the low target of $21.00 reflects risks of margin compression or competitive pressures. Recent ratings from Evercore ISI, BTIG, JP Morgan, and Citigroup are all bullish (Outperform/Buy), with no downgrades, suggesting strong institutional conviction. The wide target spread (71% from low to high) signals high uncertainty, but the bullish consensus and recent upgrades support a positive outlook.
Bulls vs Bears: CAI Investment Factors
Caris Life Sciences presents a high-risk, high-reward profile. On the bull side, the company is delivering exceptional revenue growth (78.8% YoY), improving margins, and has a strong balance sheet with $821M cash. Analyst consensus is bullish with a 74% upside to the average target. However, the stock is deeply out of favor, down 47% in a year, and trades at a lofty PS ratio of 55.55x. The key tension is whether the company can sustain its growth trajectory and achieve consistent profitability to justify its premium valuation. If it does, the stock could re-rate significantly; if not, further downside toward the 52-week low of $14.19 is possible.
Bullish
- Strong Revenue Growth: Revenue grew 78.8% YoY to $216.2M in Q1 2026, accelerating from prior quarters. This rapid top-line expansion demonstrates strong demand for Caris's AI-driven diagnostics and pharma services.
- Improving Profitability: Gross margin improved to 65.4% in Q1 2026 from 47.2% a year ago, indicating operating leverage. The company turned profitable in Q4 2025 with net income of $82.0M, and free cash flow turned positive at $22.5M in Q1 2026.
- Strong Balance Sheet: Caris holds $821.1M in cash with a current ratio of 7.85 and low debt-to-equity of 0.66. This provides ample liquidity to fund growth and weather any near-term volatility.
- Bullish Analyst Consensus: 12 analysts rate the stock a Buy with a mean score of 1.54 (1=Strong Buy). The average price target of $27.00 implies 74% upside from the current price of $15.52, with a high target of $36.00.
Bearish
- Extremely High Valuation: The trailing PS ratio of 55.55x is over 5x the biotech industry average of 8-10x. Even the forward PS of 24.6x remains very expensive, leaving little room for error.
- Earnings Volatility: Despite Q4 2025 profitability, Q1 2026 returned to a net loss of $0.5M. Net margin remains negative at -0.24%, and ROE is -0.93%, highlighting inconsistent earnings.
- Massive Price Decline: The stock is down 47.4% over the past year and 62.98% from its 52-week high of $42.50. It trades near its 52-week low of $14.19, reflecting persistent selling pressure and lack of catalysts.
- High Short Interest: The short ratio of 4.75 indicates significant bearish sentiment. A high level of short interest can lead to volatility but also suggests many investors are betting against the stock.
CAI Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of -47.37% and currently trading at $15.52, which is just 36.5% of its 52-week range (low $14.19, high $42.50). This positioning near the lower end of the range suggests the stock is deeply oversold and potentially undervalued, but also reflects persistent selling pressure and lack of bullish catalysts. The 52-week low of $14.19 is a critical support level; a break below could signal further downside, while a move above $42.50 would represent a massive breakout from the downtrend. Beta is not provided, but the stock's volatility is evident from its 62.98% maximum drawdown and sharp price swings, indicating high risk.
Beta
—
—
Max Drawdown
-63.0%
Largest decline past year
52-Week Range
$14-$43
Price range past year
Annual Return
-30.9%
Cumulative gain past year
| Period | CAI Return | S&P 500 |
|---|---|---|
| 1m | +14.5% | +2.8% |
| 3m | +23.8% | +4.2% |
| 6m | -9.1% | +11.3% |
| 1y | -30.9% | +21.5% |
| ytd | -25.9% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAI Fundamental Analysis
Revenue has grown strongly, with Q1 2026 revenue of $216.2 million representing 78.8% YoY growth, accelerating from the prior year's levels. However, the trajectory is uneven: Q4 2025 revenue was $292.9 million, suggesting some seasonality or lumpiness. The growth is driven by the core diagnostics and pharma services segments, with R&D services contributing $5.4 million in Q1 2026. The company turned profitable in Q4 2025 with net income of $82.0 million, but Q1 2026 saw a net loss of $0.5 million, highlighting earnings volatility. Gross margin improved to 65.4% in Q1 2026 from 47.2% a year earlier, indicating operating leverage, but net margin remains negative at -0.24% for the quarter. The balance sheet is strong with $821.1 million in cash and a current ratio of 7.85, while debt-to-equity is low at 0.66. Free cash flow was $22.5 million in Q1 2026, positive for the second consecutive quarter, suggesting improving cash generation. ROE is negative (-0.93) due to the net loss, but the company has ample liquidity to fund growth internally.
Quarterly Revenue
$216174000.0B
2026-03
Revenue YoY Growth
+78.8%
YoY Comparison
Gross Margin
65.4%
Latest Quarter
Free Cash Flow
$123456000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAI Overvalued?
Since net income is negative on a trailing basis (EPS -$0.0018), we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 55.55x, while the forward PS (based on estimated revenue of $1.83B) is approximately 24.6x, implying the market expects significant revenue growth. Compared to the biotechnology industry average PS of roughly 8-10x, Caris trades at a massive premium of over 500%, reflecting its high growth and AI-driven narrative. Historically, the PS ratio has ranged from 4.8x (2021) to 154x (Q4 2025), and the current 55.55x is near the middle of that range, suggesting the market is pricing in optimistic but not extreme growth expectations. The PEG ratio of 0.48 indicates the stock may be undervalued relative to its earnings growth, but this relies on forward EPS estimates of $1.04, which may be uncertain.
PE
-14.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 2x~23x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
632.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Caris's earnings are volatile, swinging from a net income of $82M in Q4 2025 to a loss of $0.5M in Q1 2026. The net margin remains negative at -0.24%, and ROE is -0.93%, indicating that profitability is not yet established. While the company has $821M in cash, its high cash burn rate in prior quarters (e.g., -$102.6M net income in Q1 2025) raises concerns about long-term capital efficiency. The debt-to-equity ratio of 0.66 is manageable, but the company's reliance on continued growth to justify its valuation is a key risk.
Market & Competitive Risks: The stock trades at a PS ratio of 55.55x, a massive premium to the biotech industry average of 8-10x. This leaves it vulnerable to valuation compression if growth slows or sentiment shifts. The stock's 1-year decline of 47.4% and beta (not provided but implied high) suggest high sensitivity to market rotations out of growth stocks. Recent news of a rotation into defensive sectors highlights this risk. Additionally, the biotech sector faces regulatory and competitive pressures that could impact Caris's AI platform adoption.
Worst-Case Scenario: If revenue growth decelerates below 50% or the company fails to achieve sustained profitability, the stock could fall to its 52-week low of $14.19, representing a 8.6% decline from the current price of $15.52. In a severe scenario, if the market re-rates the stock to a PS ratio of 20x (still above industry average), the price could drop to around $10, implying a 35% loss. The maximum drawdown of 62.98% from the high suggests that such a decline is within historical precedent.
FAQ
The key risks are: 1) Financial: Earnings volatility and negative net margin (-0.24% in Q1 2026) could persist, undermining the bull case. 2) Valuation: The high PS ratio (55.55x) leaves the stock vulnerable to multiple compression if growth slows. 3) Market: The stock is down 47% in a year and has a high short ratio of 4.75, indicating bearish sentiment and potential for further declines. 4) Competitive: The AI diagnostics space is crowded, and Caris may face pricing pressure or technological disruption. The most severe risk is a growth deceleration below 40%, which could drive the stock to its 52-week low of $14.19 or lower.
The 12-month forecast is mixed but leans bullish. The bull case (30% probability) sees the stock reaching $27-$36, driven by sustained 70%+ growth and profitability. The base case (45% probability) targets $21-$27, assuming growth moderates to 50-60% and margins improve. The bear case (25% probability) sees the stock falling to $14.19-$21 if growth decelerates below 40% or losses return. The most likely scenario is the base case, with the stock trading around the average analyst target of $27, implying 74% upside from the current price. Key assumptions include continued revenue growth and positive free cash flow.
CAI is overvalued on an absolute basis but may be undervalued relative to its growth. The trailing PS ratio of 55.55x is over 5x the biotech industry average of 8-10x, indicating a significant premium. However, the forward PS of 24.6x reflects expected revenue growth, and the PEG ratio of 0.48 suggests the stock is cheap relative to its earnings growth (based on forward EPS estimates of $1.04). Historically, the PS ratio has ranged from 4.8x to 154x, so the current 55.55x is near the middle, implying the market is pricing in optimistic but not extreme growth expectations. The valuation is justified only if the company can sustain high growth and improve margins.
CAI presents a compelling risk/reward for aggressive investors. The stock is down 47% in the past year and trades at $15.52, near its 52-week low of $14.19, with an average analyst target of $27.00 implying 74% upside. However, the trailing PS ratio of 55.55x is extremely high relative to the biotech industry average of 8-10x, and earnings are volatile (net loss of $0.5M in Q1 2026 after a profitable Q4 2025). For investors with a high risk tolerance and a long-term horizon, it could be a good buy if the company sustains its 78.8% revenue growth and achieves consistent profitability. Conservative investors may want to wait for more evidence of sustainable earnings.
CAI is better suited for long-term investment due to its high volatility and speculative nature. The stock has a 1-year decline of 47.4% and a maximum drawdown of 62.98%, making it risky for short-term trading. The company is in a high-growth phase with 78.8% revenue growth, but earnings are inconsistent. Long-term investors (3-5 years) could benefit from the AI-driven growth story if the company achieves scale and profitability. Short-term traders may find opportunities around earnings announcements, but the high short ratio and lack of near-term catalysts suggest caution. A minimum holding period of 2-3 years is recommended to allow the growth thesis to play out.